You are here

Home » Content

Tiroid kanserlerinde flor-18 florodeoksiglukoz pozitron emisyon tomografi görüntülemenin yeri

The role of 18F-fluoro-2-deoxyglucose positron emission tomography imaging in thyroid cancers

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
There has recently been an increasing number of studies demonstrating the sensitivity of 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) in the management of differentiated and de-differentiated thyroid cancers. This prospective study was planned to investigate the value of FDG PET in the follow-up of patients with thyroid cancers. With this aim 36 patients (18 male, 18 female) with differentiated thyroid cancer who had either non-physiologic I-131 uptake outside the thyroid gland in whole body scanning, high Tg levels with negative whole body I-131 scanning, Tg antibody positivity, classified in high risk group or suspicious lesions with other imaging modalities were performed FDG PET imaging. Sensitivity, specificity, positive predictive value and negative predictive value in whole of the group were 54.5%, 92.8%, 92.3% and 56.5%, respectively. Sensitivity and specificity of FDG PET in the group with TSH levels of <2 μIU/ml were 66.6% and 100%, respectively, whereas these values were 40% and 87.5%, respectively in the group with TSH levels of >30 μIU/ml. These results show that FDG PET is a valuable test in the follow-up of patients with differentiated thyroid cancers.
Bookmark/Search this post with
Abstract (Original Language): 
Son yıllarda 2-[18F]-fluoro-2-deoxy-d-glucose (F-18 FDG) pozitron emisyon tomografinin (PET) diferansiye ve de-diferansiye tiroid kanserlerinde de duyarlı bir yöntem olduğuna ilişkin çalışmaların sayısı artmıştır. Bu prospektif çalışma tiroid kanserli olguların takibinde F-18 FDG PET’in değerinin araştırılması amacıyla planlanmıştır. Bu amaçla I-131 tüm vücut taramasında tiroid yatağı dışında fizyolojik olmayan tutulum tespit edilen, Tg düzeyi yüksek ve I-131 tüm vücut taraması negatif olan, anti-Tg antikor düzeyleri yüksek olan, yüksek risk grubunda değerlendirilen veya diğer görüntüleme yöntemlerinde şüpheli bulgu tespit edilen 36 diferansiye tiroid kanserli olguya (18 erkek, 18 kadın) FDG PET görüntüleme uygulandı. Tüm grupta FDG PET’in duyarlılığı %54.5, özgüllüğü %92.8, pozitif öngörü değeri %92.3 ve negatif öngörü değeri %56.5 olarak hesaplanmıştır. TSH seviyesi <2 μIU/ml olan grupta FDG PET duyarlılığı %66.6, özgüllüğü %100 olarak hesaplanırken, TSH seviyesi >30 μIU/ml olan grupta duyarlılık %40, özgüllük %87.5 olarak bulunmuştur. Bu bulgular FDG PET’in diferansiye tiroid kanserli olguların takibinde değerli bir test olduğunu göstermektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-tiroid-kanserlerinde-flor-18-florodeoksiglukoz-pozitron-emisyon-tomografi-goruntulemenin-yeri.pdf
  • 4
229-234
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Joensuu H, Ahonen A. Imaging of metastases of thyroid
carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl
Med 1987; 28: 910-914.
2. Sisson JK, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-
2-deoxy-D-glucose by thyroid cancer: implications for
diagnosis and therapy. J Clin Endocrin Metabol 1993;
77: 1090-1094.
3. Feine U. Fluor-18-deoxyglucose positron emission
tomography in differentiated thyroid cancer. Eur J
Endocrinol 1998; 138: 492-496.
4. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18
fluorodeoxyglucose positron emission tomography in
thyroid cancer: results of a multicentre study. Eur J Nucl
Med 1999; 26: 1547-1552.
5. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha
H. Fluorine-18 fluorodeoxyglucose positron emission
tomography and iodine-131 whole-body scintigraphy
in the follow-up of differentiated thyroid cancer. Eur J
Nucl 1997; 24: 1342-1348.
6. Hosaka Y, Tawata M, Kurihara A, Ohtaka M, Endo
T, Onaya T. The regulation of two distinct glucose
transporter (GLUT1 and GLUT4) gene expressions in
cultured rat thyroid cells by thyrotropin. Endocrinology
1992; 131: 159-165.
7. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H,
Müller-Schauenburg W. Fluorine-18-FDG and iodine-
131-iodide uptake in thyroid cancer. J Nucl Med 1996;
37: 1468-1472.
8. Wang W, Macapinlac H, Finn R, et al. PET scanning
with 18F- fluoro-2-deoxyglucose can localize residual
differentiated thyroid cancer in patients with negative
I-131 whole body scans. J Clin Endocrinol Metab 1999;
84: 2291-2302.
9. Schlüter B, Bohuslavizki KH, Beyer W, et al. Impact of
FDG PET on patients with differentiated thyroid cancer
who present with elevated thyroglobulin and negative
131-I scan. J Nucl Med 2001; 42: 71-76.

Thank you for copying data from http://www.arastirmax.com